NCLEX-RN • Physiological Integrity

IV Therapy Complications (Infiltration/Extravasation)

Recognizing and managing two critical IV complications that threaten tissue integrity and patient safety.

A stethoscope, heartbeat, and checked clinical chart representing the nursing licensure exam.
Inside this lesson 10 sections 5 questions 6 figures

SECTION 1

Historical Context & Motivation

Intravenous therapy is one of the most common invasive procedures performed in healthcare, with over 80% of hospitalized patients receiving some form of IV access during their stay. While this route of administration provides rapid, reliable drug delivery and fluid resuscitation, it also introduces significant risks—chief among them infiltration and extravasation. The history of IV therapy is inseparable from the history of efforts to prevent and manage these complications, and understanding that evolution is essential for every nurse entering clinical practice.

1832 • First Therapeutic IV Infusion

Thomas Latta administered saline intravenously to cholera patients in Scotland. Crude equipment led to frequent tissue damage, infection, and what we now recognize as infiltration events.

1940s • Standardized IV Equipment

World War II drove mass production of sterile, single-use IV tubing and glass bottles. Plastic catheters gradually replaced metal needles, reducing but not eliminating catheter-related tissue injury.

1980s • Vesicant Drug Protocols Emerge

Growing use of chemotherapy agents highlighted the devastating effects of extravasation. The Oncology Nursing Society published early guidelines for vesicant administration and antidote use.

2006 • INS Standards of Practice

The Infusion Nurses Society (INS) codified evidence-based standards for IV insertion, site assessment, and complication grading, establishing the infiltration scale still used in clinical settings today.

2021 • Updated INS 2021 Standards

INS released revised standards emphasizing vascular visualization technology, standardized documentation, and expanded extravasation antidote protocols aligned with current pharmacologic evidence.

Despite these advances, infiltration and extravasation remain among the most frequently reported IV complications, with incidence rates ranging from 22% to 67% depending on the patient population and catheter dwell time. The central clinical question for the bedside nurse is twofold: How do you detect these complications early, and how do you intervene to minimize tissue damage? This lesson provides the knowledge framework to answer both questions with confidence.

SECTION 2

Core Principles & Definitions

Before examining clinical management, it is essential to establish precise definitions and distinguish between infiltration and extravasation. Although these terms are sometimes used interchangeably in casual clinical conversation, they represent fundamentally different levels of risk and demand different nursing interventions. Both involve the unintended leakage of fluid from the intravascular space into surrounding tissue, but the nature of the infusate determines the severity classification and the appropriate response.

1

Infiltration

The inadvertent administration of a nonvesicant solution or medication into the surrounding tissue. Examples include normal saline, lactated Ringer's, and most antibiotics. Tissue damage is generally reversible.
2

Extravasation

The inadvertent administration of a vesicant agent into surrounding tissue. Vesicants—such as chemotherapy drugs (doxorubicin, vincristine), vasopressors (dopamine, norepinephrine), and hypertonic solutions—can cause blistering, tissue necrosis, and permanent injury.
3

Vesicant vs. Irritant

Vesicants cause tissue destruction (necrosis, blistering) even in small volumes. Irritants cause pain and inflammation along the vein but do not typically cause necrosis. Both require prompt attention, but vesicants demand emergency intervention.
4

Phlebitis vs. Infiltration

Phlebitis is inflammation of the vein wall itself—characterized by warmth, redness, and a palpable venous cord. Unlike infiltration, the infusate remains intravascular. Phlebitis may precede infiltration as vascular integrity deteriorates.
5

Risk Factors

Key risk factors include fragile veins (elderly, neonates), prolonged catheter dwell time (>72–96 hours), site location over joints, high infusion rates or osmolality, and patient movement. Awareness of these factors guides both prevention and assessment frequency.
✦

KEY TAKEAWAY

Think of infiltration and extravasation like a water hose springing a leak. If the hose is carrying clean water (nonvesicant), the lawn gets soggy but recovers—that is infiltration. If the hose is carrying herbicide (vesicant), the leaked fluid kills the grass around it—that is extravasation. The mechanism of leakage is identical; the danger depends entirely on what is leaking. This distinction drives every clinical decision that follows.

SECTION 3

Visual Explanation — Infiltration vs. Extravasation

Infiltration vs. Extravasation — Cross-Sectional ViewINFILTRATION (Nonvesicant)EXTRAVASATION (Vesicant)Vein LumenCatheter TipEdematous AreaFluid leaks into tissueSigns: Cool skin, pallor,edema, decreased flow rateTissue recoversVein LumenCatheter TipNecrotic ZoneBlistering / necrosisVesicant leaks into tissueSigns: Pain, burning, blistering,skin breakdown, ulcerationMay cause permanent tissue lossBoth involve catheter dislodgement from the vein — the infusate type determines severity
This diagram compares the pathophysiology of infiltration (left) and extravasation (right). Both begin with catheter dislodgement from the vein lumen, causing fluid to enter the surrounding interstitial tissue. In infiltration, the nonvesicant fluid causes edema and coolness but the tissue recovers. In extravasation, the vesicant agent causes blistering, necrosis, and potential permanent tissue destruction.

As illustrated above, the catheter tip in both scenarios has migrated out of the vein lumen, either through mechanical dislodgement (patient movement, poor securement) or through erosion of the vein wall (prolonged dwell time, chemical irritation). The leaked fluid accumulates in the subcutaneous and interstitial spaces. In infiltration, the tissue response is primarily osmotic and hydrostatic—fluid shifts cause local edema, and the skin becomes cool and pale because the interstitial fluid compresses superficial capillaries. In extravasation, the vesicant agent binds to cellular structures and directly damages or destroys tissue, producing an inflammatory cascade that can progress to full-thickness necrosis over hours to days if untreated.

SECTION 4

Pathophysiologic Mechanism & Assessment

Mechanism of Injury

The mechanism of tissue injury in extravasation depends on the pharmacologic properties of the vesicant. DNA-binding vesicants such as doxorubicin intercalate into cellular DNA and are released from dead cells to damage adjacent cells, creating an expanding zone of necrosis over days to weeks. Non-DNA-binding vesicants such as vincristine cause cell death through osmotic or metabolic disruption but do not persist in tissue, so the damage is generally more limited and self-contained. Vasopressors like norepinephrine cause intense local vasoconstriction that produces ischemic necrosis by depriving tissue of perfusion. Understanding these distinct mechanisms is critical because the antidote strategy differs for each class.

The INS Infiltration Scale

The Infusion Nurses Society developed a standardized grading scale to quantify infiltration severity and guide clinical decision-making. This tool is a core assessment framework tested on the NCLEX-RN. It evaluates skin color, temperature, edema extent, and the presence of tissue damage using a 0–4 grading system.

GradeSkin AppearanceEdemaNursing Action
Grade 0No symptomsNoneContinue monitoring per protocol
Grade 1Skin blanched, cool to touch< 1 inch in any directionDiscontinue infusion; elevate extremity; apply warm/cold compress per policy
Grade 2Skin blanched, cool; with or without pain1–6 inches in any directionDiscontinue; elevate; estimate volume extravasated; notify provider
Grade 3Skin blanched, translucent; cool; may have numbness> 6 inches in any directionDiscontinue; elevate; notify provider; document extensively; may require antidote
Grade 4Skin tight, leaking, discolored, bruised, swollen; blistered or pitting edemaGross edema; circulatory impairment possibleDiscontinue; antidote if vesicant; urgent provider notification; possible surgical consult

INS Infiltration Scale (Grades 0–4)

⚠

NCLEX Alert

The NCLEX-RN frequently tests the distinction between infiltration and extravasation in priority-setting and delegation questions. Remember: Extravasation is always more urgent than infiltration because of the potential for irreversible tissue destruction. When triaging multiple patients, the patient with suspected vesicant extravasation takes priority.

SECTION 5

Classification of Vesicants & Antidotes

Effective management of extravasation requires that the nurse not only recognize the complication but also identify the specific vesicant involved and administer the correct antidote. The pharmacologic class of the extravasated agent determines whether the intervention strategy is spread-and-dilute or localize-and-neutralize. DNA-binding agents such as doxorubicin are managed by localized cooling and specific antidotes (dexrazoxane) because dispersing the drug would enlarge the injury zone. Non-DNA-binding agents like vinca alkaloids benefit from warm compresses and hyaluronidase to disperse and dilute the agent across a larger tissue volume, minimizing the concentration at any single point.

Extravasation Management Decision FlowchartExtravasation Suspected1. STOP the infusion immediatelyDo NOT remove the catheter yet2. Aspirate residual drug via catheterThen remove the IV catheterIdentify the vesicant classDNA-Binding Vesicant(e.g., doxorubicin, daunorubicin)• Apply COLD compresses (15–20 min q6h)• Administer dexrazoxane IV (if available)• Do NOT apply DMSO with dexrazoxaneStrategy: LOCALIZE & NEUTRALIZENon-DNA-Binding Vesicant(e.g., vincristine, vasopressors)• Apply WARM compresses (15–20 min q6h)• Administer hyaluronidase SQ• For vasopressors: phentolamine SQStrategy: SPREAD & DILUTE
This flowchart outlines the sequential nursing actions when extravasation is suspected. After stopping the infusion and aspirating residual drug, the nurse identifies the vesicant class to determine whether the management strategy is localize-and-neutralize (cold, dexrazoxane) or spread-and-dilute (warm, hyaluronidase/phentolamine).
Vesicant AgentClassificationAntidoteThermal Tx
Doxorubicin (Adriamycin)DNA-binding anthracyclineDexrazoxane IV or topical DMSOCold compresses
VincristineNon-DNA-binding vinca alkaloidHyaluronidase (subcutaneous)Warm compresses
NorepinephrineVasopressorPhentolamine (subcutaneous)Warm compresses
DopamineVasopressorPhentolamine (subcutaneous)Warm compresses
Calcium chloride/gluconateElectrolyte (high osmolality)Hyaluronidase (subcutaneous)Warm compresses

Common Vesicant Agents and Their Antidotes

SECTION 6

Worked Example — Clinical Scenario

The following worked example walks through the clinical reasoning process a nurse would use when encountering a suspected IV complication. It integrates assessment findings, the INS infiltration scale, and evidence-based interventions.

Scenario: Mrs. Delgado — Doxorubicin Infusion

  1. 1

    Step 1 — Assess the Clinical Findings

    Mrs. Delgado, a 58-year-old patient with breast cancer, is receiving doxorubicin via a peripheral IV in her left forearm. Thirty minutes into the infusion, she reports burning pain at the IV site. On inspection, you observe: the site is edematous approximately 3 inches in diameter, the skin is blanched and cool to touch, and there is redness surrounding the area. The infusion pump shows no occlusion alarm.
    INS Grade 2–3 infiltration with burning pain — vesicant extravasation must be suspected
  2. 2

    Step 2 — Immediate Actions (First 60 Seconds)

    The first priority is to STOP the infusion immediately. Do not flush the line. Disconnect the IV tubing from the catheter hub, but leave the catheter in place. Using a small (3–5 mL) syringe, attempt to aspirate as much residual drug and blood as possible through the catheter. This step can reduce the vesicant volume in the tissue. After aspiration attempts, remove the IV catheter.
    Infusion stopped → aspirated 1.5 mL of blood-tinged fluid → catheter removed
  3. 3

    Step 3 — Identify the Vesicant Class and Select Antidote

    Doxorubicin is a DNA-binding anthracycline vesicant. The management strategy is localize-and-neutralize. The antidote of choice is dexrazoxane (Totect), administered intravenously within 6 hours of the extravasation. If dexrazoxane is unavailable, topical DMSO 99% may be applied to the site every 8 hours for 7 days. Do NOT combine dexrazoxane and DMSO—they are used as alternatives, not together.
    Notified oncologist → dexrazoxane ordered → cold compresses applied 15 min on / 15 min off
  4. 4

    Step 4 — Apply Thermal Treatment

    Because doxorubicin is a DNA-binding agent, COLD compresses are applied to the extravasation site for 15–20 minutes every 6 hours for the first 24–48 hours. Cold causes local vasoconstriction that limits the spread of the drug into surrounding tissue. Warm compresses would be contraindicated here because they would increase perfusion and spread the vesicant further. Elevate the affected extremity above heart level to reduce edema.
    Cold compresses applied; extremity elevated; warm compresses avoided (DNA-binding vesicant)
  5. 5

    Step 5 — Document and Monitor

    Thorough documentation includes: date and time of the event, estimated volume of drug extravasated, the INS infiltration grade, a photograph (per institutional policy), the patient's subjective symptoms, all interventions performed and their times, and the provider's notification time and orders received. Monitor the site every 4 hours for progression of edema, blistering, or skin breakdown. A plastic surgery or wound care consult may be necessary if tissue necrosis develops.
    Complete documentation filed; follow-up assessment q4h × 72 hours; patient educated on signs of worsening

SECTION 7

Infiltration vs. Extravasation — Comprehensive Comparison

The following comparison table consolidates the key distinctions between infiltration and extravasation across multiple clinical dimensions. On the NCLEX-RN, these differences are tested through scenario-based questions that require you to prioritize interventions, identify the correct thermal treatment, and select the appropriate antidote. Internalizing this comparison framework will strengthen your clinical decision-making in both exam and practice settings.

FeatureInfiltrationExtravasation
Infusate typeNonvesicant (NS, LR, most antibiotics)Vesicant (chemo agents, vasopressors, hypertonic solutions)
Key symptomsEdema, cool skin, pallor, decreased flow rate, taut skinBurning pain, blistering, erythema, skin breakdown, necrosis
Skin temperatureCool to touchMay be warm (inflammatory response) or cool
Tissue damageReversible; no necrosisPotentially irreversible; blistering, necrosis, ulceration
Priority levelModerate — requires attention but not emergentHIGH — time-sensitive emergency requiring antidote
First actionStop infusion, remove catheter, elevate extremityStop infusion, aspirate residual drug, THEN remove catheter
AntidoteNot applicableAgent-specific: dexrazoxane, hyaluronidase, phentolamine
Thermal treatmentWarm or cold per institutional policyCold for DNA-binding vesicants; Warm for non-DNA-binding vesicants

Side-by-Side Comparison: Infiltration vs. Extravasation

✦

KEY TAKEAWAY

For NCLEX test-taking strategy, remember the mnemonic: "DNA = Don't Need warmth, Apply cold." DNA-binding vesicants (anthracyclines like doxorubicin) require cold compresses to localize the agent. Non-DNA-binding agents (vincristine, vasopressors) require warm compresses to disperse and dilute. This thermal treatment distinction is among the most commonly tested extravasation concepts. Think of it like a chemical spill: if the substance gets worse when it spreads (DNA-binder), you contain it with cold; if the substance is less dangerous when diluted, you use warmth to encourage absorption across a wider area.

SECTION 8

Connection to Advanced Practice & Prevention Strategies

While the NCLEX-RN primarily tests recognition and immediate management of infiltration and extravasation, understanding the broader clinical context strengthens both exam performance and practice readiness. Advanced concepts include central venous access devices (CVADs) as a prevention strategy for vesicant administration, vascular access specialist roles, and institutional quality improvement programs aimed at reducing IV complication rates. Many facilities now mandate that vesicant chemotherapy agents be administered exclusively through CVADs (PICC lines, ports, tunneled catheters) rather than peripheral IVs, significantly reducing extravasation risk.

ConceptNCLEX-RN LevelAdvanced Practice Level
AssessmentINS infiltration scale; subjective and objective findingsUltrasound-guided assessment; compartment pressure monitoring
PreventionSite selection, catheter securement, regular assessment q1–2hVein visualization technology; CVAD for all vesicants; extravasation risk scoring tools
InterventionStop infusion, aspirate, antidote, thermal therapySubcutaneous washout (saline flush-out technique); surgical debridement; flap reconstruction
DocumentationEvent description, grade, interventions, provider notificationRoot cause analysis; incident reporting systems; trend analysis for unit-level QI

NCLEX-RN vs. Advanced Practice Scope

Prevention remains the gold standard. The INS 2021 Standards of Practice recommend: selecting the smallest gauge catheter appropriate for the prescribed therapy, avoiding sites over areas of flexion, securing the catheter with a manufactured stabilization device rather than tape alone, assessing the IV site at least every 1–2 hours for peripheral lines, and educating the patient to report any pain, swelling, or discomfort immediately. For high-risk populations—neonates, elderly patients, those with fragile veins or altered sensation—assessment frequency should be increased. As you advance in practice, you will encounter extravasation prevention bundles that combine these strategies into standardized protocols, reducing complication rates by as much as 50% in published studies.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A nursing student asks, "What is the main difference between infiltration and extravasation?" How would you explain this distinction in a way that emphasizes clinical significance?
Show answer
Both infiltration and extravasation involve the leakage of IV fluid from the vein into surrounding tissue, typically due to catheter dislodgement or vein wall erosion. The critical distinction is the nature of the infusate. Infiltration involves nonvesicant solutions (e.g., normal saline, lactated Ringer's) that cause local edema but generally do not damage tissue permanently. Extravasation involves vesicant agents (e.g., chemotherapy drugs, vasopressors) that can cause blistering, tissue necrosis, and permanent injury. This distinction is clinically significant because extravasation requires immediate, agent-specific antidote administration and is considered a medical emergency, while infiltration typically resolves with supportive care alone.

Question 2: BASIC CALCULATION

You assess a patient's IV site and find the following: skin is blanched and cool, there is edema extending approximately 4 inches from the insertion site, and the patient reports mild discomfort. Using the INS Infiltration Scale, what grade would you assign, and what nursing actions are indicated?
Show answer
Based on the INS Infiltration Scale, these findings correspond to a Grade 2 infiltration: blanched, cool skin with edema measuring 1–6 inches in any direction. The appropriate nursing actions include: (1) immediately discontinuing the infusion, (2) removing the IV catheter, (3) elevating the affected extremity above heart level to promote venous return and reduce edema, (4) applying warm or cold compresses per institutional protocol, (5) estimating the volume of fluid that may have extravasated, and (6) notifying the provider and documenting the event with the assigned grade, time, and all interventions performed.

Question 3: INTERMEDIATE

A patient receiving vincristine through a peripheral IV develops swelling, pain, and redness at the IV site. The nurse suspects extravasation. Describe the correct sequence of interventions, including the appropriate antidote and thermal treatment, and explain the rationale for each step.
Show answer
The correct sequence is: (1) Stop the vincristine infusion immediately to prevent additional vesicant from entering the tissue. (2) Leave the catheter in place and aspirate as much residual drug as possible using a small syringe—this reduces the drug concentration in the tissue. (3) Remove the IV catheter after aspiration. (4) Administer hyaluronidase subcutaneously around the extravasation site, injecting 0.2 mL in five separate points around the perimeter. Hyaluronidase is an enzyme that breaks down hyaluronic acid in connective tissue, promoting dispersion and dilution of the vincristine across a larger tissue volume to reduce concentration-dependent damage. (5) Apply warm compresses for 15–20 minutes every 6 hours for 24–48 hours—warmth promotes vasodilation and drug absorption, consistent with the 'spread-and-dilute' strategy for non-DNA-binding vesicants. (6) Elevate the extremity, notify the provider, and document thoroughly.

Question 4: APPLIED

You are a charge nurse triaging four patients with IV-related concerns. Patient A has a Grade 1 infiltration with NS infusing. Patient B reports burning at the site where dopamine is running via peripheral IV, with 2 inches of edema. Patient C has redness along the vein with D5W running and no edema. Patient D has a PICC line with doxorubicin infusing and no site complaints. In what order should you assess these patients and why?
Show answer
The priority order is B → A → C → D. Patient B requires immediate assessment because dopamine is a vasopressor (vesicant), and the combination of burning pain and edema strongly suggests extravasation. This patient needs the infusion stopped immediately, phentolamine administered subcutaneously as an antidote, and warm compresses applied. Delay could result in ischemic necrosis from unopposed vasoconstriction. Patient A is assessed next because Grade 1 infiltration with NS is low-risk but still requires discontinuation and site evaluation. Patient C likely has phlebitis (vein wall inflammation without tissue infiltration), which warrants IV removal and site rotation but is not an emergency. Patient D has the lowest priority because the PICC line is the appropriate access device for vesicant chemotherapy and the patient has no complaints—however, the nurse should still perform a scheduled site assessment. This question illustrates the principle that vesicant extravasation always outranks nonvesicant infiltration in clinical priority.

Question 5: CRITICAL THINKING

A facility reports a 35% incidence rate of peripheral IV infiltration among elderly patients on a medical-surgical unit. As a newly licensed RN participating in a quality improvement committee, propose an evidence-based prevention bundle and explain the physiologic rationale behind each component.
Show answer
An evidence-based infiltration prevention bundle for elderly patients should include five key components. First, vein visualization technology (near-infrared or ultrasound-guided insertion) should be used for all peripheral IV starts, as elderly patients have fragile, tortuous veins with decreased subcutaneous tissue, making blind insertion more likely to cause vessel trauma. Second, the smallest gauge catheter appropriate for the therapy (typically 22–24 gauge) should be selected to minimize mechanical irritation of the vein intima. Third, manufactured catheter stabilization devices should replace traditional tape securement because elderly skin is thin and mobile, increasing the risk of catheter migration. Fourth, assessment frequency should be increased to every hour (rather than every 2 hours), since elderly patients may have decreased pain sensation due to peripheral neuropathy and may not report early symptoms. Fifth, a 72-hour maximum dwell time policy should be enforced, with routine site rotation and documentation. The physiologic rationale for this bundle reflects the unique vascular changes of aging: decreased collagen and elastin in vein walls, reduced peripheral perfusion, and age-related sensory deficits that delay symptom reporting. Published evidence suggests that prevention bundles combining these elements can reduce infiltration rates by 40–50%.

SUMMARY

Lesson Summary

Summary

Infiltration and extravasation are the two primary complications arising from IV catheter dislodgement or vein wall erosion. Both involve leakage of infusate into surrounding tissue, but the clinical severity depends on the nature of the infusate. Infiltration involves nonvesicant solutions and produces reversible edema, cool skin, and pallor. Extravasation involves vesicant agents (chemotherapy, vasopressors, hypertonic solutions) that can cause blistering, necrosis, and permanent tissue destruction. The INS Infiltration Scale (Grades 0–4) provides a standardized framework for grading severity and guiding interventions.

Management of extravasation follows a critical sequence: stop the infusion → aspirate residual drug → remove catheter → identify the vesicant class → administer the correct antidote → apply appropriate thermal therapy. For DNA-binding vesicants (e.g., doxorubicin), the strategy is localize-and-neutralize using cold compresses and dexrazoxane. For non-DNA-binding vesicants (e.g., vincristine, vasopressors), the strategy is spread-and-dilute using warm compresses and agent-specific antidotes (hyaluronidase or phentolamine). Prevention remains paramount: proper catheter securement, appropriate site selection, regular assessment every 1–2 hours, and use of central venous access devices for vesicant administration are all evidence-based strategies endorsed by the INS 2021 Standards of Practice.

Varsity Tutors • NCLEX-RN • IV Therapy Complications (Infiltration/Extravasation)